Tapentadol placed in schedule II in the US and filed in the EU
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's centrally acting analgesic tapentadol is to be placed in schedule II of the Controlled Substances Act in the US, the Drug Enforcement Administration has concluded in a final rule.